Your browser doesn't support javascript.
loading
Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
Sun, Kai; Chen, Wen-Min; Wang, Xu; Zhao, Xiao-Su; Li, Ling-Di; Hao, Yue; Wang, Jun; Xu, Nan; Jiang, Qian; Jiang, Hao; Xu, Lan-Ping; Wang, Yu; Zhang, Xiao-Hui; Huang, Xiao-Jun; Qin, Ya-Zhen.
Affiliation
  • Sun K; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chen WM; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wang X; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhao XS; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Li LD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Hao Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wang J; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Xu N; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Qin YZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Hematol Oncol ; 41(3): 594-597, 2023 08.
Article de En | MEDLINE | ID: mdl-36516881

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie-lymphome lymphoblastique à précurseurs B / Leucémie-lymphome lymphoblastique à précurseurs B et T Aspects: Patient_preference Limites: Adult / Humans Langue: En Journal: Hematol Oncol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie-lymphome lymphoblastique à précurseurs B / Leucémie-lymphome lymphoblastique à précurseurs B et T Aspects: Patient_preference Limites: Adult / Humans Langue: En Journal: Hematol Oncol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni